FDA Approves Aucatzyl for Adults With Relapsed or Refractory B-Cell Precursor ALL

The FDA approved Aucatzyl, a CD19-directed genetically modified autologous T-cell immunotherapy, for adults with ...

NOVEMBER 12, 2024

FDA Grants Accelerated Approval to Iclusig With Chemotherapy for Newly Diagnosed Ph+ ALL

The FDA granted accelerated approval to Iclusig with chemotherapy for adult patients with newly diagnosed ...

MARCH 20, 2024

BiTE Therapy Shows Promise in R/R ALL

Although only a phase 1b dose-finding study in patients with relapsed/refractory (R/R) B-cell precursor acute ...

MARCH 16, 2022

Studies Point to Optimal Dosing in Acute Leukemia and Lymphoma

Two new studies of drugs already licensed for cancer—one indicated for ALL and one approved for both ALL and ...

JANUARY 18, 2022

Managing Asparaginase Hypersensitivity Reactions

Asparaginase-based regimens are gaining a foothold in the treatment of acute lymphoblastic leukemia (ALL) and ...

JANUARY 14, 2022

Hospitals Take Lead Role In Newest Gene Cancer Rx

Two revolutionary new cancer therapies that use genetic engineering to treat ALL and certain types of lymphoma are ...

DECEMBER 2, 2017

Reducing Infection Risk in Young Leukemia Patients

The first few weeks is a crucial stage in monitoring and preventing infection in these children.

SEPTEMBER 14, 2017

FDA Approves Kymriah, First Gene Therapy in U.S.

CAR T-cell therapy approved to treat certain children and young adults with B-cell acute lymphoblastic leukemia.

AUGUST 31, 2017

FDA Approves Besponsa for Adults With Relapsed or Refractory ALL

Pfizer's new drug is the first and only CD22-directed antibody–drug conjugate indicated for the treatment of ...

AUGUST 17, 2017

FDA Grants New Pediatric Indication for Blincyto

Blinatumomab met its primary Phase II endpoint in 93 children with ALL of complete remission within the first two ...

OCTOBER 14, 2016